Patent ID: 11970530
Assignee: ASTRAZENECA, AB
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method for treating ovarian cancer, fallopian tube cancer, primary peritoneal cancer, breast cancer, and/or pancreatic cancer in a subject, the method comprising:, administering to the subject a therapeutically effective amount of bevacizumab, and, administering to the subject a therapeutically effective amount of 4-[(3-{[4-(cyclopropane-carbonyl)piperazine-1-yl]carbonyl}-4-fluorophenyl)methyl]-2H-phthalazin-1-one (olaparib), or a hydrate, solvate, or prodrug thereof,
wherein the therapeutically effective amount of bevacizumab is in the range of about 10 to 20 mg/kg of body weight every 3 weeks;
wherein the therapeutically effective amount of olaparib is about 300 mg twice daily;
wherein the therapeutically effective amount of olaparib reduces Common Terminology Criteria for Adverse Events (CTCAE) Grade 2, Grade 3, or Grade 4 hypertension in the subject as compared to hypertension in the subject when the subject receives bevacizumab alone; and
wherein the progression free survival is at least about 4 months greater than for subjects receiving bevacizumab alone.